Encompass Health Corp

EHC

Held by 2 specialist biotech funds

Share on X

Fund Holdings

Deerfield Management Eventide Asset Management

AI Signal

AI analyst context — unlock full analysis

Position Trend

Feb 13, 2026

$7.3M

1 fund

Feb 17, 2026

$1.6M

1 fund

-78% total institutional value over 2 quarters

Catalysts

No catalysts tracked.

Position Details

Deerfield ManagementNEWFeb 17, 2026

Shares: 15,259Value: $1.6M

# Signal Note: Deerfield initiates $1.6M position in Encompass Health Deerfield's entry into EHC (15,259 shares, $1.6M) signals confidence in the rehabilitation services operator's operational recovery and margin expansion post-COVID normalization. The position timing aligns with improving inpatient rehabilitation facility (IRF) utilization rates and favorable reimbursement dynamics, though the $1.6M stake size suggests conviction rather than major portfolio weighting. Key catalysts include Q3/Q4 2024 margin trends and any M&A activity in the consolidating post-acute care space.

Eventide Asset ManagementNEW

More EHC Analysis

Insider buy/sell details with names, titles, and amounts
AI-generated context for every signal

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

DOCS2 funds EW2 funds CELC2 funds IRON2 funds BBIO2 funds ARWR2 funds STE2 funds ZTS

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

**Signal Note: Eventide initiates $7.3M EHC position** Eventide's entry into Encompass Health—a post-acute care operator with no direct drug pipeline—suggests conviction in rehabilitation services exposure, likely driven by aging demographics and potential Medicare reimbursement tailwinds. This aligns with Eventide's healthcare thesis but represents a shift toward care delivery rather than therapeutic innovation, warranting monitoring of Q3/Q4 2024 earnings for admission volume and margin trends.